The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial
Abstract
PURPOSE: -adrenergic receptor agonist, was assessed among men with symptoms of overactive bladder (OAB) receiving pharmacologic treatment for benign prostatic hyperplasia (BPH) in a phase 3 randomized controlled trial. MATERIALS AND METHODS: Men ≥ 45 years with OAB symptoms and BPH, treated with α-blocker with/without 5α-reductase inhibitors, were randomized 1:1 to vibegron or placebo for 24 weeks. Coprimary end points were change from baseline at week 12 in mean daily micturitions and urgency episodes. Secondary end points were change from baseline at week 12 in mean nightly nocturia and daily urge urinary incontinence episodes, International Prostate Symptom Score‒storage score, and volume voided per micturition. Safety was evaluated via adverse events (AEs). RESULTS: < .0001). AE rates were similar in vibegron (45.0%) and placebo (39.0%) arms; AEs occurring in ≥ 2% of participants were hypertension (9.0% vs 8.3%), COVID-19 (4.0% vs 3.1%), UTI (2.5% vs 2.2%), and hematuria (2.0% vs 2.5%). CONCLUSIONS: In this trial, vibegron met all primary and secondary end points and was safe and well tolerated in men with OAB symptoms and pharmacologically treated BPH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
Coupland, C. A. C., Hill, T., Dening, T., Morriss, R., Moore, M., & Hippisley-Cox, J. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0677 · Cited by 637
Anticholinergic drugs and risk of dementia: case-control study
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., et al. (2018) · BMJ · doi:10.1136/bmj.k1315 · Cited by 520
The psychological impact of overactive bladder: A systematic review
Kinsey, D., Pretorius, S., Glover, L., & Alexander, T. (2016) · Journal of Health Psychology · doi:10.1177/1359105314522084 · Cited by 113
Research works printed but not linked: 23
- Berry, 1984, The development of human benign prostatic hyperplasia with age, J Urol., 132, 474, 10.1016/S0022-5347(17)49698-4 · DOI · Paper page
- 2022, The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet Healthy Longev., 3, e754, 10.1016/S2666-7568(22)00213-6 · DOI · Paper page
- Lerner, 2021, Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management, J Urol., 206, 806, 10.1097/JU.0000000000002183 · doi:10.1097/ju.0000000000002183
- D'Ancona, 2019, The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction, Neurourol Urodyn., 38, 433, 10.1002/nau.23897 · DOI · Paper page
- Cameron, The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder, J Urol
- Coyne, 2008, The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study, BJU Int., 101, 1388, 10.1111/j.1464-410X.2008.07601.x · DOI · Paper page
- Burnett, 2020, Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: a retrospective observational study, Neurourol Urodyn., 39, 1378, 10.1002/nau.24348 · DOI
- Goldman, 2016, Real-world patterns of care for the overactive bladder syndrome in the United States, Urology., 87, 64, 10.1016/j.urology.2015.09.025 · DOI
- Abreu-Mendes, 2020, Pharmacology of the lower urinary tract: update on LUTS treatment, Ther Adv Urol., 12, 1756287220922425, 10.1177/1756287220922425 · DOI
- Sandhu, 2024, Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023, J Urol., 211, 11, 10.1097/JU.0000000000003698 · DOI · Paper page
- Staskin, 2020, International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR, J Urol., 204, 316, 10.1097/JU.0000000000000807 · DOI · Paper page
- Nitti, 2013, Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies, Int J Clin Pract., 67, 619, 10.1111/ijcp.12194 · DOI · Paper page
- Frankel, 2022, Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR, Adv Ther., 39, 959, 10.1007/s12325-021-01972-8 · DOI
- Su, 2020, The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis, Medicine (Baltimore)., 99, e18802, 10.1097/MD.0000000000018802 · doi:10.1097/md.0000000000018802
- Kaplan, 2020, Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS), J Urol., 203, 1163, 10.1097/JU.0000000000000738 · doi:10.1097/ju.0000000000000738
- Herschorn, 2021, Mirabegron vs placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a safety analysis from the randomized, phase 4 PLUS study, Urology., 147, 235, 10.1016/j.urology.2020.09.040 · DOI
- Matsukawa, 2019, Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies, Neurourol Urodyn., 38, 941, 10.1002/nau.23935 · doi:10.1002/nau.23935
- Rutman, 2019, Once-daily vibegron, a novel oral β3 agonist, does not inhibit CYP2D6, a common pathway for drug metabolism in patients on OAB medications, J Urol., 201, e231
- Gallegos, 2008, Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia, Pharmacotherapy., 28, 356, 10.1592/phco.28.3.356 · DOI
- Yuan, 2015, Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis, Medicine (Baltimore)., 94, e974, 10.1097/MD.0000000000000974 · DOI
- Dmochowski, 2021, Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis, Neurourol Urodyn., 40, 28, 10.1002/nau.24536 · DOI
- Zillioux, 2022, SUFU white paper on overactive bladder anticholinergic medications and dementia risk, Neurourol Urodyn., 41, 1928, 10.1002/nau.25037 · DOI
- Welk, 2020, Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study, BJU Int., 126, 183, 10.1111/bju.15040 · DOI
Metadata
- Authors
- Staskin, D., Owens-Grillo, J., Thomas, E., Rovner, E., Cline, K., & Mujais, S.
- Venue
- Journal of Urology
- Published
- 2024-08
- Volume
- 212
- Issue
- 2
- Pages
- 256-266
- ISSN
- 0022-5347
- 1527-3792
- Cited by
- 30
- References
- 3
- Language
- en
- Funders
- Sumitomo Pharma America (None)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. https://app.cochat.ai/papers/10.1097/ju.0000000000003999
- The paper
- Staskin, D., Owens-Grillo, J., Thomas, E., Rovner, E., Cline, K., & Mujais, S. (2024). Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. Journal of Urology. https://doi.org/10.1097/ju.0000000000003999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.